One study investigating STAT-targeting drugs for ADPKD therapies suggested pimozide inhibits STAT5, crizotinib inhibits STAT3 phosphorylation, and pyrimethamine inhibits STAT3 by dimerization (Strubl et al. 2020). This evidence concerns the gene SOAT1 and autosomal dominant polycystic kidney disease.